- Home
- RFM vs AGEN Comparison
RFM vs AGEN Comparison
Compare RFM & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RFM
- AGEN
- Stock Information
- Founded
- RFM 2020
- AGEN 1994
- Country
- RFM United States
- AGEN United States
- Employees
- RFM N/A
- AGEN N/A
- Industry
- RFM Finance/Investors Services
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- RFM Finance
- AGEN Health Care
- Exchange
- RFM Nasdaq
- AGEN Nasdaq
- Market Cap
- RFM 92.3M
- AGEN 96.2M
- IPO Year
- RFM N/A
- AGEN 2000
- Fundamental
- Price
- RFM $15.35
- AGEN $3.83
- Analyst Decision
- RFM
- AGEN Buy
- Analyst Count
- RFM 0
- AGEN 3
- Target Price
- RFM N/A
- AGEN $10.50
- AVG Volume (30 Days)
- RFM 20.7K
- AGEN 399.9K
- Earning Date
- RFM 01-01-0001
- AGEN 03-13-2025
- Dividend Yield
- RFM 9.74%
- AGEN N/A
- EPS Growth
- RFM N/A
- AGEN N/A
- EPS
- RFM N/A
- AGEN N/A
- Revenue
- RFM N/A
- AGEN $160,427,000.00
- Revenue This Year
- RFM N/A
- AGEN N/A
- Revenue Next Year
- RFM N/A
- AGEN $36.13
- P/E Ratio
- RFM N/A
- AGEN N/A
- Revenue Growth
- RFM N/A
- AGEN 59.00
- 52 Week Low
- RFM $12.89
- AGEN $2.50
- 52 Week High
- RFM $16.41
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- RFM 53.96
- AGEN 65.58
- Support Level
- RFM $14.95
- AGEN $3.08
- Resistance Level
- RFM $15.21
- AGEN $3.29
- Average True Range (ATR)
- RFM 0.12
- AGEN 0.27
- MACD
- RFM 0.06
- AGEN 0.08
- Stochastic Oscillator
- RFM 100.00
- AGEN 94.84
About RFM RiverNorth Flexible Municipal Income Fund Inc.
RiverNorth Flexible Municipal Income Fund Inc is a diversified, closed-end management investment company. Its primary investment objective is to seek current income exempt from regular U.S. federal income taxes. The fund's secondary investment objective is total return.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).